Almost all patients who received CAR-T cell therapy prior to allo-HSCT2 achieved CR (including 9 patients who were MRD+) except for 4 patients (2 AML patients failed to respond and received CD33+ and CD123+ CAR-T respectively; 2 B-ALL patients failed to respond and received CD19+CAR-T). This evidence concerns the gene CD19 and acute myeloid leukemia.